Progression of Tau Pathology in AD
AD 中 Tau 蛋白病理学的进展
基本信息
- 批准号:6570773
- 负责人:
- 金额:$ 31.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-02-01 至 2007-11-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer's disease casein kinase clinical research confocal scanning microscopy human tissue immunocytochemistry in situ hybridization microarray technology neurofibrillary tangles neurons northern blottings pathologic process phosphorylation prosencephalon protein isoforms protein structure tau proteins
项目摘要
DESCRIPTION (provided by applicant): The Neurofibrillary Tangles (NFTs) are found mainly in highly vulnerable long projection neurons in the Alzheimer's disease (AD) brain. The cholinergic neurons of the cholinergic basal forebrain (CBF) are exquisitely prone to NFT formation, and a progression of cellular changes is associated with tangle formation. However, the molecular events that underlie the formation of these lesions by the microtubule-associated tau protein remain unknown. Studies on the in vitro assembly of tau protomers into filaments strongly suggest that tau's transition from the soluble to the fibrillar form can be driven, in part, by phosphorylation and by C-terminal truncation accomplished in part by the action of caspases. Additionally, isoforms of the casein kinase 1 (CK1) phosphokinase family that deposit in granulovacuolar degeneration bodies (GVDs) are upregulated 10-30 fold in end stage AD.
We propose to determine the order of appearance of these tau alterations in correlation with NFT formation in the cholinergic basal forebrain (CBF) long projection neurons. We hypothesize that the formation of the fibrillar pathologies is induced by a definable sequence of molecular events that directly impact tau "s assembly competency through phosphorylation and truncation. We will test this hypothesis by accomplishing the following specific aims: 1. Using antibodies against specific tau phosphopeptides, we propose to determine whether CBF neurons exhibit a progression of site-specific phosphorylation events that correlates with the transition from non-cognitive impairment (NCI), to mild cognitive impairment (MCI), early, and end-stage Alzheimer's disease (AD); 2. We propose to determine the progression of C-terminal tau truncation using well-characterized antibodies to D421 (the caspase site) and E 391 (another truncation site known to occur in AD); 3. Using antibodies to CKIalpha, CK1delta, and CKIepsilon, we will assay for the appearance of GVD bodies in CBF neurons during the progression from NCI-->MCI-->AD; and, 4. Using gene array technology, we propose to determine the relative quantities of CK1 message and the amounts of caspase message in individual CBF neurons from patients with the aforementioned clinical diagnoses.
描述(由申请人提供):神经元缠结(NFT)主要存在于阿尔茨海默病(AD)大脑中高度脆弱的长投射神经元中。胆碱能基底前脑(CBF)的胆碱能神经元非常容易形成NFT,并且细胞变化的进展与缠结形成相关。然而,微管相关tau蛋白形成这些病变的分子基础仍然未知。对tau蛋白原聚体体外组装成细丝的研究强烈表明,tau蛋白从可溶性到纤维状形式的转变可以部分地通过磷酸化和部分地通过半胱天冬酶的作用完成的C-末端截短来驱动。此外,粒空泡变性体(GVD)中存款的酪蛋白激酶1(CK 1)磷酸激酶家族的亚型在终末期AD中上调10-30倍。
我们建议,以确定这些tau蛋白的改变与NFT形成的胆碱能基底前脑(CBF)长投射神经元的外观顺序。我们假设纤维状病变的形成是由一系列可定义的分子事件诱导的,这些分子事件通过磷酸化和截短直接影响tau蛋白的组装能力。我们将通过实现以下具体目标来检验这一假设:1。使用针对特定tau磷酸肽的抗体,我们提出确定CBF神经元是否表现出与从非认知障碍(NCI)到轻度认知障碍(MCI)、早期和终末期阿尔茨海默病(AD)的转变相关的位点特异性磷酸化事件的进展; 2.我们建议使用针对D421(半胱天冬酶位点)和E 391(已知在AD中发生的另一个截短位点)的充分表征的抗体来确定C末端tau截短的进展; 3.使用CK 1 α、CK 1 δ和CK 1 β的抗体,我们将检测从NCI->MCI->AD进展过程中CBF神经元中GVD小体的出现;以及,4.使用基因阵列技术,我们建议确定CK 1信息的相对数量和caspase信息的数量在个别CBF神经元从上述临床诊断的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lester Irvin Binder其他文献
Lester Irvin Binder的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lester Irvin Binder', 18)}}的其他基金
Tau Nitration and Oxidation in Alzheimer's Disease
阿尔茨海默病中 Tau 蛋白的硝化和氧化
- 批准号:
7450632 - 财政年份:2009
- 资助金额:
$ 31.7万 - 项目类别:
Tau Nitration and Oxidation in Alzheimer's Disease
阿尔茨海默病中 Tau 蛋白的硝化和氧化
- 批准号:
7896582 - 财政年份:2009
- 资助金额:
$ 31.7万 - 项目类别:
TAU TRUNCATION AND CONFORMATION IN AD PROGRESSION
AD 进展中的 TAU 截断和构象
- 批准号:
6927756 - 财政年份:2005
- 资助金额:
$ 31.7万 - 项目类别:
ALTERED TAU CONFORMATION AS AN EARLY MARKER IN AD
TAU 构象的改变作为 AD 的早期标志
- 批准号:
6299299 - 财政年份:2000
- 资助金额:
$ 31.7万 - 项目类别:
ALTERED TAU CONFORMATION AS AN EARLY MARKER IN AD
TAU 构象的改变作为 AD 的早期标志
- 批准号:
6098279 - 财政年份:1999
- 资助金额:
$ 31.7万 - 项目类别:
ALTERED TAU CONFORMATION AS AN EARLY MARKER IN AD
TAU 构象的改变作为 AD 的早期标志
- 批准号:
6295530 - 财政年份:1999
- 资助金额:
$ 31.7万 - 项目类别:
相似国自然基金
casein kinase I alpha在卵母细胞减数分裂成熟和克隆胚胎发育中对染色体分离作用的研究
- 批准号:31160243
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Computer-aided design and development of isoform selective inhibitors of Casein Kinase 1
酪蛋白激酶 1 异构体选择性抑制剂的计算机辅助设计和开发
- 批准号:
10629703 - 财政年份:2023
- 资助金额:
$ 31.7万 - 项目类别:
Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis
在真菌发病机制中靶向酪蛋白激酶 1 (CK1) 样激酶 Yck2
- 批准号:
10437100 - 财政年份:2022
- 资助金额:
$ 31.7万 - 项目类别:
Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis
在真菌发病机制中靶向酪蛋白激酶 1 (CK1) 样激酶 Yck2
- 批准号:
10595027 - 财政年份:2022
- 资助金额:
$ 31.7万 - 项目类别:
Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents
类固醇增强选择性酪蛋白激酶抑制剂:同类首创的新型吸入式抗哮喘药物
- 批准号:
nhmrc : 1137171 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别:
Development Grants
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
开发用于治疗脑癌的新型酪蛋白激酶 1 抑制剂
- 批准号:
10531565 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别:
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
开发用于治疗脑癌的新型酪蛋白激酶 1 抑制剂
- 批准号:
9698320 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
酪蛋白激酶-1-δ 在原发性和转移性乳腺癌中的治疗靶向
- 批准号:
10524031 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别:
Targeting casein kinase 1-alpha for cancer therapy
靶向酪蛋白激酶 1-α 进行癌症治疗
- 批准号:
10553872 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别:
Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents
类固醇增强选择性酪蛋白激酶抑制剂:同类首创的新型吸入式抗哮喘药物
- 批准号:
nhmrc : GNT1137171 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别:
Development Grants
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
酪蛋白激酶-1-δ 在原发性和转移性乳腺癌中的治疗靶向
- 批准号:
9710619 - 财政年份:2018
- 资助金额:
$ 31.7万 - 项目类别: